Organogenesis Holdings (ORGO) Free Cash Flow Growth (1y) (2017 - 2026)
Organogenesis Holdings (ORGO) Free Cash Flow Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 44.93% |
| 10 | Organogenesis Holdings | 323.97 Mn | 231.87 Mn | 11.46 Mn | 176.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 176.32% |
| Dec 31, 2025 | 358.92% |
| Sep 30, 2025 | -86.22% |
| Jun 30, 2025 | -2,667.58% |
| Mar 31, 2025 | -115.21% |
| Dec 31, 2024 | 3.92% |
| Sep 30, 2024 | 352.72% |
| Jun 30, 2024 | -83.75% |
| Mar 31, 2024 | -55.00% |
| Dec 31, 2023 | 355.25% |
| Sep 30, 2023 | 51.02% |
| Jun 30, 2023 | 1,227.58% |
| Mar 31, 2023 | -1,442.14% |
| Dec 31, 2022 | -122.45% |
| Sep 30, 2022 | -144.40% |
| Jun 30, 2022 | -105.90% |
| Mar 31, 2022 | 92.68% |
| Dec 31, 2021 | -28.52% |
| Sep 30, 2021 | 269.11% |
| Jun 30, 2021 | 214.29% |